NEPTUNUS: The medical device business is less affected by centralized procurement, and the company's significant matters are still ongoing

NEPTUNUS today received research visits from several institutions including Dongfang Caifu Securities and Deyuan Investment, as well as some individual investors. During the research activities, the company stated that its medical device segment primarily operates on an agency sales model, representing several well-known domestic and international brands such as Boston Scientific, Johnson & Johnson, and Mindray Medical. The company's medical device revenue for 2023 has exceeded 12 billion yuan. Compared to the pharmaceutical business, the medical device business is less affected by centralized procurement. In addition, the company has management and sales elites from leading industry firms such as Boston Scientific and Siemens, ensuring professionalism and advanced management concepts in the medical device field. Furthermore, the company is still undergoing significant matters and will fulfill its information disclosure obligations in a timely manner according to relevant laws and regulations

Source: Zhitong The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.